Oxigene Neu-Sensamide NDA may reference Sensamide pivotal data, FDA has told company -- CEO.
Executive Summary
OXIGENE NEU-SENSAMIDE RADIATION SENSITIZER ON TRACK FOR 1998 NDA filing, Oxigene CEO Bjorn Nordenvall, PhD, indicated during a UBS Securities conference in London April 15. A Phase III trial of the high-dose metoclopramide formulation will be completed by the second quarter of 1998, putting the drug on track for a 1999 launch, Nordenvall estimated. The company plans to use a Phase III trial of an earlier formulation, Sensamide, to support the application. FDA has told the company that data from the two formulations can be included in the Neu-Sensamide NDA, Nordenvall said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth